Company Overview and News

4
BeiGene Reports Second Quarter 2018 Financial Results

2018-08-09 globenewswire
CAMBRIDGE, Mass. and BEIJING, China, Aug. 09, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported recent business highlights and financial results for the second quarter and first half of 2018.
CICHY CELGZ MRTX CELG BGNE CICHF CCB 0939

2
MRTX / Mirati Therapeutics, Inc. FORM 8-K (Current Report)

2018-08-08 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 MRTX

11
Mirati Therapeutics: Innovating Stellar Molecules For Cancer Treatment

2018-08-07 seekingalpha
Mirati is a gift that keeps on giving, as the company logged astronomical profits for shareholders.
BRK.A CELGZ AZN MRTX CELG BGNE NVS LLY BMY

2
MRTX / Mirati Therapeutics, Inc. 10-Q (Quarterly Report)

2018-08-01 sec.gov
Document Table of Contents UNITED STATES
MRTX

2
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

2018-08-01 zacks
The Invesco DWA SmallCap Momentum ETF (DWAS - Free Report) was launched on 07/19/2012, and is a passively managed exchange traded fund designed to offer broad exposure to the Small Cap Blend segment of the US equity market.
PLUS AXGN MRTX

2
Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar?

2018-07-09 zacks
Launched on 07/19/2012, the Invesco DWA SmallCap Momentum ETF (DWAS - Free Report) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Blend segment of the US equity market.
AXGN MRTX MGPI CVRR

67
CNNX / CONE Midstream Partners LP - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-29 fintel.io
CONE Midstream Partners LP (NYSE:CNNX) has 4 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7,112,254 shares. Largest shareholders include Noble Energy Inc, MetLife Securities, Inc, Dreman Value Management, L L C, and Acorn Wealth Advisors, Llc. CONE Midstream Partners LP (NYSE:CNNX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.
NBL MRTX CNNX CNXM

65
CLOK / Cipherloc Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-29 fintel.io
Cipherloc Corp. (OTC:CLOK) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,200,000 shares. Largest shareholders include Manchester Management Pr, Llc. Cipherloc Corp. (OTC:CLOK) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.
CLOK MRTX

66
ALES / Evans Brewing Co Inc - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-28 fintel.io
Evans Brewing Co Inc (OTC:ALES) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Evans Brewing Co Inc (OTC:ALES) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
ALES MRTX

65
ECOR / electroCore, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-27 fintel.io
electroCore, Inc. (NASDAQ:ECOR) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . electroCore, Inc. (NASDAQ:ECOR) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
MRTX ECOR

65
GLU / Gabelli Global Utility & Income Trust (The) - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-27 fintel.io
Gabelli Global Utility & Income Trust (The) (AMEX:GLU) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Gabelli Global Utility & Income Trust (The) (AMEX:GLU) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
GLU MRTX

65
XERS / XERIS PHARMACEUTICALS INC - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-27 fintel.io
XERIS PHARMACEUTICALS INC (NASDAQ:XERS) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . XERIS PHARMACEUTICALS INC (NASDAQ:XERS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
XERS MRTX AUTL

80
GBR / New Concept Energy, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-27 fintel.io
New Concept Energy, Inc. (AMEX:GBR) has 4 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 79,523 shares. Largest shareholders include Price T Rowe Associates Inc /md/, Vanguard Group Inc, Virtu Financial LLC, and UBS Group AG. New Concept Energy, Inc. (AMEX:GBR) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.
UBS VIRT MRTX GBR ULSGF

65
GMGI / Golden Matrix Group, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-06-27 fintel.io
Golden Matrix Group, Inc. (OTC:GMGI) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include . Golden Matrix Group, Inc. (OTC:GMGI) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
GMGI MRTX

MRTX: Mirati Therapeutics Analysis and Research Report

2018-06-26 - Asif

Overview Mirati Therapeutics, Inc. is a clinical-stage oncology company developing product candidates to address the genetic, epigenetic and immunological promoters of cancer. The company's precision oncology clinical programs utilize next-generation genomic testing to identify and select cancer patients who are most likely to benefit from targeted drug treatment. In immuno-oncology, Mirati Therapeutics is advancing clinical programs where the ability of its product candidates to improve the immune environment of tumor cells may enhance and expand the efficacy of existing cancer immunotherapy medicines when given in combination. The company's preclinical programs include potentially first-in-class and best-in-class product candidates specifically designed to address mutations and tumors where few treatment options exist. The company approach each of its discovery and development programs with a singular focus: to translate its deep understanding of the molecular drivers of canc...

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 60468T105